Background/Aims: In testing for non-inferiority of anti-infective drugs, the primary endpoint is often the difference in the proportion of failures between the test and control group at a landmark time. The landmark time is chosen to approximately correspond to the qth historic quantile of the control group, and the non-inferiority margin is selected to be reasonable for the target level q. For designing these studies, a troubling issue is that the landmark time must be prespecified, but there is no guarantee that the proportion of control failures at the landmark time will be close to the target level q. If the landmark time is far from the target control quantile, then the pre-specified non-inferiority margin may not longer be reasonable. Exact variable margin tests have been developed by Röhmel and Kieser to address this problem, but these tests can have poor power if the observed control failure rate at the landmark time is far from its historic value. Methods: We develop a new variable margin non-inferiority test where we continue sampling until a pre-specified proportion of failures, q, have occurred in the control group, where q is the target quantile level. The test does not require any assumptions on the failure time distributions, and hence, no knowledge of the true qth control quantile for the study is needed. Results: Our new test is exact and has power comparable to (or greater than) its competitors when the true control quantile from the study equals (or differs moderately from) its historic value. Our nivm R package performs the test and gives confidence intervals on the difference in failure rates at the true target control quantile. The tests can be applied to time to cure or other numeric variables as well. Conclusion: A substantial proportion of new anti-infective drugs being developed use non-inferiority tests in their development, and typically, a pre-specified landmark time and its associated difference margin are set at the design stage to match a specific target control quantile. If through changing standard of care or selection of a different population the target quantile for the control group changes from its historic value, then the appropriateness of the pre-specified margin at the landmark time may be questionable. Our proposed test avoids this problem by sampling until a pre-specified proportion of the controls have failed.
Introduction
New anti-infective drugs are often tested using noninferiority clinical trials against previously developed drugs. In 2014, of the 10 drugs approved by the US Food and Drug Administration (FDA) 1, 2 for treatment of infectious diseases, half used a non-inferiority trial in their clinical development. Consider isavuconazole (under development), used for treating invasive aspergillosis, a life-threatening infection seen in immunocompromised patients. 3 A non-inferiority study compared the test drug (isavuconazole) to a control drug (voriconazole) for all-cause mortality by the landmark time (day 42), with a pre-specified margin of 10%. Isavuconazole would be declared non-inferior if the difference between the test and control failure rates at day 42 was statistically significantly less than 10%. This 10% margin was based on historic failure rates at day 42 of 18.8% for the control treatment, and for this historic rate, the margin of 10% was reasonable to the regulatory agency. In the non-inferiority study, the control failure rates at day 42 matched the historical rates fairly well (52=258 = 20:2%), and the test drug had similar rates (48=258 = 18:6%). Since the upper limit of the 95% confidence interval on the percent difference was less than 10%, isavuconazole was declared non-inferior.
Consider the potential problem of the control treatment failure rates at the landmark time being considerably less than the historic rates. If the observed failure rates for the control treatment were 10% in the noninferiority study, then the 10% margin may be too large to reasonably declare non-inferiority. When planning a study, we cannot guarantee that the failure rates for control treatment will be close to the historic rates, so we would like to be able to adjust the margin in a statistically rigorous way according to the observed control failure rates. One approach is to use variable noninferiority margins that change based on the control rate. 4, 5 For example, Ro¨hmel and Kieser 5 continue to use a pre-specified landmark time, but through the variable non-inferiority margin make it difficult to declare non-inferiority if the control failure rate is less than the historic one. Although that approach protects against unreasonable non-inferiority declarations, this approach has low power if the control failure rate at the landmark time was poorly predicted. Our approach, the control quantile method, is different. We follow patients until a pre-specified proportion of the control treatment group fail and then develop tests and confidence intervals using data up until that time. The control quantile method retains proper type I error rates, protects against unreasonable non-inferiority findings, and importantly retains reasonable power if the control failure rates have changed since the historic rates were measured.
The control quantile method may be applied to time to cure as well as other numeric endpoints. For example, in section ''Application 2: percent reduction in lesion at day 3 for dalbavancin,'' we consider a trial with the endpoint of percent reduction in skin lesions at day 3. For ease of exposition, we primarily refer to the endpoint of analysis as time to failure.
Review of non-inferiority tests with fixed or variable margins
Fixed margin tests at landmark time Let F 1 (t) and F 2 (t) be the cumulative distributions for the control and test treatment failure times, respectively. Let t 0 be a pre-specified landmark time. A simple non-inferiority hypotheses on the failure times at t 0 is
where d.0 is the non-inferiority margin. Let x 1 [x 1 (t 0 ) and x 2 [x 2 (t 0 ) be the number of failures by t 0 in the control group and the treatment group, respectively. The associated random variables have X a (t 0 );Binomial(n a , F a (t 0 )), where n a is the number of subjects in group a, and a = 1, 2. We can use tests or confidence intervals on the difference in proportions for these hypotheses; 6, 7 however, these methods on the difference in proportions may not be testing the most appropriate hypotheses, as we discuss in the next section.
Motivation and choice of a variable margin
For the fixed margin test, ideally the landmark time t 0 is approximately t[F À1 1 (q), where q is some target control failure rate. For the isavuconazole study, t 0 = 42 days, d = 0:10, and the historical control rate was 18:8%, so a reasonable q is q = 0:20.
In practice, F 1 for the upcoming study is unknown, so we cannot pre-specify both t 0 and q. If F hist 1 is the historical control distribution, then t 0 is chosen such thatF
, through selection of different patients, change of care over time, or evolution of infecting pathogens, we could have F 1 (t 0 ) very different from F hist 1 (t 0 ). Under these new conditions, the margin d may no longer be sensible. As an extreme case, if we estimate that F 1 (t 0 ) = 0:01 after the non-inferiority study was completed, then the margin d = 0:10 would not make sense, since ifF 1 (t 0 ) = F 1 (t 0 ), then only 1% of the patients on control treatment are expected to die by t 0 , but a test treatment with up to 10 times higher failure rates at t 0 would be defined as non-inferior. The current practice is to negotiate with the regulatory agency a landmark time, t 0 , with q'F hist 1 (t 0 ) and hope that the control failure rates at t 0 are close to q in the non-inferiority study. This is not an ideal situation since there is uncertainty about what to do if the control rates from the noninferiority study are very much less than the target (or even how to define ''very much less'').
When t 0 is not approximately t = F À1 1 (q), another approach is to use variable non-inferiority margins for the difference in proportions that change based on the control rate. 4, 5 These methods redefine the hypotheses as
where dfÁg is the variable margin function for the difference. These hypotheses are typically calibrated so that df g is smooth with dfF 1 (t)g = d. We rewrite the hypotheses in equation (2) as
where gfF 1 (t)g = dfF 1 (t)g + F 1 (t). The hypotheses in equation (3) do not require a pre-specified t 0 close to t = F À1 1 (q) like the hypotheses in equation (1) . Furthermore, the hypotheses in equation (3) have more flexibility than comparing hazard ratios under proportional hazards 4 (Chapter 13). The null hypothesis in equation (3) holds for all t and hence represents the entire distributions, F 1 and F 2 . If we reject the null, then for some t we conclude that F 2 (t) À F 1 (t)\dfF 1 (t)g. If t 0 't, then the test will be powerful when F 2 (t) À F 1 (t) is small. The main issue with these hypotheses is defining gf g so that for every t we get a sensible noninferiority margin, although typically our focus is on the region around t 0 or t.
The function gf g partitions the space of all values of the points fF 1 (t), F 2 (t)g into a null region (gray in Figure 1 ) or an alternative region (white in Figure 1 ).
For a specific landmark time t 0 , if you can show that the point fF 1 (t 0 ), F 2 (t 0 )g is significantly in the alternative region, then you have rejected the null hypothesis. This does not require choosing t 0 to equal F À1 1 (q). Consider some choices for gf g. Suppose all we cared about is the hypotheses in equation (1) except with t 0 replaced with t = F À1 1 (q)
Since t is unknown and there are no restrictions on F 1 and F 2 , in order to rigorously test the hypotheses in equation (4), we choose gf g as a least-favorable-like function. Figure 1 (4) are not a practical set of Figure 1 . Different choices for the variable margin function, gfF 1 (t)g. Gray is the null region, and white is the alternative region. All four panels have F 1 (t) = 0:20 and gfF 1 (t)g = 0:10. In terms of the alternative hypotheses, the panels represent the following: (a)
:71 for t<t and F 2 (t)\F 1 (t) + 0:10 for t.t.
hypotheses; the point t with F 1 (t) = 0:80 and F 2 (t) = 0:40 is in the null region, despite this point signifying that the test drug has substantially lower failure rates than the control drug after 80% of the controls have failed. Figure 1 (b) depicts a constant difference margin of 10%. This is not sensible since the point with F 1 (t) = 0:01 and F 2 (t) = 0:10 would be in the alternative region, showing that a test drug with 10 times the failure rate of the control drug is non-inferior. Figure  1 (c) depicts a constant odds ratio margin of C = 1:71 (so that at F 1 (t) = 0:20, the value of F 2 (t) = 0:30 would be on the boundary). This margin avoids the problem with the constant difference boundary because as F 1 (t) ! 0, the boundary approaches the point (F 1 (0) = 0, F 2 (0) = 0). Finally, Figure 1 (d) gives a margin with constant odds ratio of C = 1:71 for t t (with F 1 (t) = 0:20) and a constant difference of 0.10 for t.t, as proposed by Ro¨hmel and Kieser. 5 
Testing on variable margins with t 0 fixed
An exact test for the hypotheses in equation (3) with fixed t 0 and x a = x a (t 0 ) for a = 1, 2 is given as follows. Define W (x 1 , x 2 ) such that smaller values are less likely under the null hypothesis, and W ( Á , Á ) meets Barnard's convexity requirement
Then, a valid (i.e. exact) one-sided p-value can be calculated by maximizing over the margin the probability of equal or more extreme responses 5 (equation (3)). Specifically, a one-sided exact p-value for testing the margin g with fixed t 0 is
where f bin is a binomial probability mass function, and the maximum is over pairs fF 1 (t 0 ),
g. the thick solid black lines in Figure 1 ). Ro¨hmel and Kieser 5 discuss four tests for variable margins based on the observed proportions at a landmark time. Two of these tests are exact (T 3 and T 4 in their notation). The first of these (T 3 ) is motivated by a margin similar to Figure 1(d) , and in our notation, W ( Á , Á ) is the maximum of two p-values: one from an exact conditional test for the odds ratio and one from an asymptotic test on the difference. The second exact test (T 4 ) is more powerful and is a generalization of a test of Barnard. That test orders the possible values of the points (x 1 , x 2 ) by defining W (n 1 , 0) as the lowest value and sequentially defining the next higher W value as at the point that meets Barnard's convexity requirement and increases by the smallest amount the probability of rejection on the margin with ties going to fewer events in the treatment group. The rule for breaking of ties is somewhat arbitrary, but having fewer ties will increase the power of the test without sacrificing the exactness property. This Barnard-Ro¨hmel-Kieser test is quite computationally intensive.
For these exact variable margin tests, any point (F 1 (t 0 ), F 2 (t 0 )) that is in the null space will have probability of rejection less than or equal to the significance level, a. So the test is valid without any restrictions on F 1 and F 2 and regardless of how close t = t 0 is to t. The problem is that if t 0 is chosen too small, then the power can be very small under an alternative where
In the next section, we introduce the ''control quantile test'' that avoids this power problem while retaining both the validity and flexibility of variable margins of the tests of Ro¨hmel and Kieser.
Control quantile test

Continuous failure times
Let T a(1) \ Á Á Á \T a(n a ) be the continuous failure times in group a. Our proposed test procedure is to reject if x 2 (T 1(i) ) is low, where i is specified using a predetermined proportion in the control group, i=n 1 . For fixed T 1(i) , then
By the continuity assumption and the probability integral transformation, F 1 (T 1(i) ) is the ith order statistic from a sample of n 1 uniform random variables, and
9 (pp. 54 and 230). In Figure 2 , we plot the densities of F 1 (T 1(i) ) when i = (0:20 n 1 ) for n 1 = 100, 400, and 1600. Let F 1 (T 1(i) ) = U . Then, on the boundary between the hypotheses in equation (3), the binomial parameter for
1 (U )g, and unconditionally, its probability mass function is
where f beta is the beta probability density function. Importantly, the distribution of X 2 does not depend on F 1 or F 2 , but only on their relationship on the boundary through gf g. We calculate f X 2 using numeric integration. The (one-sided) p-value of the control quantile test for the hypotheses in equation (3) is
For fixed i, the power to reject when
where I(A) = 1 if A is true and 0 otherwise. Any i will give an exact test, and the choice of i will determine which part of the alternative space will drive the power to reject. Since our primary interest is at alternatives at the target quantile, t (where F 1 (t) = q), we choose i so that i = n 1 q d e, the largest integer less than or equal to n 1 q. By choosing this value, as the sample size gets larger, the test focuses more and more tightly around the difference in distributions at t (see Figure 2) . Alternatively, we could choose the smallest i that maximizes the power when F 1 = F 2 , but that strategy is not recommended because it may emphasize different places in the alternative space which may require much longer follow-up leading to longer trials.
If the time to event is a positive event like cure, then we would test the alternative that F 2 (t).gfF 1 (t)g for some t, and the p-value is calculated analogously, p
f X 2 (j; g, i).
Allowing tied failure times
Now consider the case where tied failure times are allowed. Although this section is notationally cumbersome, the basic idea is to assume that ties are caused by grouping of the failure times into observable bins. We consider two adjustments, a conservative one and a more approximate one. Assume that the failure times occur in continuous time, but we can only observe whether a failure time has occurred or not at a finite amount of assessment times.
Let the assessment times be 0 = a 0 \a 1 \ Á Á Á \a K \'. We observe x 1 (a k ) and x 2 (a k ) for k = 1, . . . , K. For example, if we only observe the failure times to the nearest day, then the assessment times could be defined as midnight at each day.
Let
) be the number of failures in each group that occur in (a kÀ1 , a k . Let ' be defined so that
Since for the hypotheses in equation (3) higher values of x 2 (T 1(i) ) make it harder to reject, the conservative adjustment is to use x 2c = x 2 (a ' ) in place of x 2 (T 1(i) ) in equation (7). For testing an alternative in the opposite direction (i.e. F 2 (t).gfF 1 (t)g), then lower values of x 2 (T 1(i) ) make it harder to reject, and the conservative adjustment is to use
Now we develop an approximate method for when the conservativeness needed to ensure strict validity is not required. Let T 1(i) be the (unobserved) jth largest of the m 1' failure times for the control group so that j = i À x 1 (a 'À1 ). Since we cannot observe the failures within (a 'À1 , a ' , we make the convenience assumption that the failures for both groups are equally distributed within that interval. Imagine a plot of m ' = m 1' + m 2' failures from both groups and imagine drawing failures (from both groups combined) at random until we get the jth failure from the control group out of the m 1' . Then, Y, the number of draws it takes to get that jth control failure, is distributed inverse hypergeometric with mean j(m ' + 1)=(m 1' + 1) 10 (pp. 255-256). Then, the number of treatment failure draws, Y À j, represents x 2 (T 1(i) ) À x 2 (a 'À1 ). So, to estimate the unobservable x 2 (T 1(i) ), for this approximate method we use x 2a , where
where we round up if the non-integer part is 0.5 for testing the hypotheses in equation (3) and round down if the inequality in the alternative is reversed. If 
t. Gray dotted line is
F 1 = F 2 .
Confidence intervals
The effect of interest is
where F 1 (t) = q and q are known and fixed, and D(q) 2 ½Àq, 1 À q. We can obtain an upper confidence limit for D(q) by inverting a series of hypothesis tests associated with a class of g functions in equation (3) (see Casella and Berger, 9 Section 9.2.1 for general discussion on inverting hypothesis tests to get confidence sets). For example, one class is the constant difference functions given by g D (F 1 (t)) = F 1 (t) + D, with Figure 1(b) representing one element in the series, g 0:10 . Then, the upper 100(1 À a=2)% one-sided limit is the value D U , such that the control quantile test gives a=2 = p cq (X, g D U ) (or D U = 1 À q, if no such solution exists). The lower 100(1 À a=2)% one-sided limit, D L , is analogous and
exists). Those two limits can be combined to give a
Now consider the constant odds ratio function (e.g. Figure 1(c) ). Let c(q, D) be the odds ratio when
Solving for F 2 (t), we get a series of functions that depend on D (and a fixed q), and replacing t with arbitrary t, we get the series of g functions
The confidence intervals are calculated exactly as for the constant difference functions except using equation (9) for g D (F 1 (t) ). Now consider the class of functions like in Figure  1(d) , some of which are plotted in Figure 3 . We call one of these margins a quantile difference margin with an odds ratio taper (QuaDMORT). When D ! 0, then
And, when D\0, we use equation (10), except we replace min with max. As with the other cases, we invert a series of hypothesis tests to get the confidence interval. For each of the margins in Figure 3 , we can calculate a one-sided p-value for the associated test. All of the margins that fail to reject at the a=2 level represent a one-sided 100(1 À a=2) confidence set. Then, we repeat this process for the other one-sided test. The two-sided 100(1 À a) confidence set is the union of those sets. We represent the set as the interval at t for D = F 2 (t) À F 1 (t).
Comparison of control quantile test to Barnard-Rö hmel-Kieser test
The control quantile tests have power comparable to that of the Barnard-Ro¨hmel-Kieser test using t 0 = t, the most powerful of the exact fixed landmark tests of Ro¨hmel and Kieser. 5 Since both the control quantile test and the Barnard-Ro¨hmel-Kieser test are exact, the salient comparison is power. Figure 4 shows that the power of the Barnard-Ro¨hmel-Kieser test depends on the value of F 1 (t 0 ), while the power of the control quantile test has a constant value of 86.8% since the followup does not stop at t 0 but stops at the random variable T 1(i) . If t 0 = t, then the power of the Barnard-Ro¨hmel-Kieser test is 85.7%, slightly smaller than the control quantile test. If t 0 is chosen at F 1 (t 0 ) = 0:25, then the power of the Barnard-Ro¨hmel-Kieser test is 89.8% and slightly larger than the control quantile test. Importantly, if t 0 is much smaller than t, then the Barnard-Ro¨hmel-Kieser test power can be greatly diminished (see Figure 4) . Thus, by changing the study design, the control quantile test protects against poorly powered studies while achieving nearly the maximum power of its competitor. (3) at the 0.025 significance level. For designing a study with these parameters, we need a sample size of n 1 = n 2 = 436 to have at least 90% power under the alternative that F 1 = F 2 . This sample size is calculated in R by first installing and loading our nivm R package, when using the call: powerNicqTest (power = 0.90, q = 0.2, delta0 = 0.1). In contrast, the sample size for an exact non-inferiority test on the difference in proportions (using the score test as the test statistic with StatXact 9, Cytel) at t 0 with margin 0.10 and F 1 (t 0 ) = F 2 (t 0 ) = 0:20 and one-sided significance level of 2:5% is n 1 = n 2 = 340 for 90% power or n 1 = n 2 = 257 for 80.43% power. So, the QuaDMORT method needs a larger sample size because it protects against unreasonable rejections when F 1 (t 0 ) ( 0:20.
Because the raw data are not publicly available, we simulate data based on a simple model. Kaplan-Meier curves are available and show very similar distributions for both groups (Figure 20 of FDA   3 ), with about 20% (30%) of the failures occurring by day 42 (84). We use the same exponential cure model for both groups, where 60% of the subjects are cured, and the other 40% have exponential failure distributions with mean = 60.59, giving F 1 (42) = F 1 (42) = 0:20 and F 1 (84) = F 2 (84) = 0:30. We simulate data using the sample sizes from the study, n 1 = n 2 = 258, assuming administrative censoring at day 100 using the nivm R package (see demo(''create.IsaSimData'')). That simulated data have x 2 (T 1(i) ) = 57 using i = 52, and the control quantile p-value is p = 0:032 (which is .0:025) with 95% confidence interval on F 2 (t) À F 1 (t) of ( À 0:051, 0:105). This simulated study just barely fails to demonstrate non-inferiority at the margin of 0.10.
Application 2: percent reduction in lesion at day 3 for dalbavancin Now consider two studies, DISCOVER 1 and 2, each comparing dalbavancin to control drugs (vancomycin and linezolid) for skin infections. A primary efficacy response is percent reduction in skin lesion size at 48-72 h post-study drug initiation. For simplicity, we consider only subjects that have percent reduction measured at 48-72 h (over 97% of subjects had that efficacy response measured). Thus, for this illustration, the sample sizes of DISCOVER 1 are as follows: dalbavancin (n = 281) and vancomycin/linezolid (n = 277), and those for DISCOVER 2 are as follows: dalbavancin (n = 363) and vancomycin/linezolid (n = 358). We plot the proportion of the patients who had percent reduction less than or equal to different values in Figure 5 . Those who had an increase are counted as no reduction in the graph.
There is a slight non-significant difference in the control curves between the two studies. For example, if we defined a success as having percent reduction in lesion size of greater than or equal to 20% as recommended by the FDA, 11 then DISCOVER 1 has 22=281 = 7:8% failed in the control group, while DISCOVER 2 has 38=363 = 10:5% failed in the control group. The FDA Guidance 12 recommends a 10% margin for noninferiority for this endpoint, but it is based in part on data from 1940 or earlier (see also Talbot et al., whose Figure 1 comes from a study published in 1940). This points to the difficulty of defining non-inferiority margins, since the 10% margin was picked without the benefit of knowing that the control group failure rates from the studies would be so low.
For the control quantile test, we define a failed response as percent reduction less than or equal to the percent reduction in the lowest 20% percentile of the control group so that F 1 (t) = 0:20, and the margin is set to 10% at t. We use the QuaDMORT variable margin function. For DISCOVER 1, we have n 1 = 277, so i = 56, and X 2 (T 1(56) ) = 68 out of n 2 = 281. The difference in proportion of failures is 68=281 À 56=277 = 0:2420 À 0:2022 = 0:0398. So, dalbavancin looks slightly worse. The control quantile test p-value is 0.081 with 95% confidence interval on F 2 (t) À F 1 (t) equal to ( À 0:029, 0:125), not quite showing non-inferiority at the 10% margin. For DISCOVER 2, the difference in failure proportions is The control quantile test p-value is 0.0054 with 95% confidence interval on F 2 (t) À F 1 (t) equal to ( À 0:051, 0:078), showing non-inferiority at the 10% margin.
Discussion
We have developed the control quantile non-inferiority test that uses a variable margin motivated by Ro¨hmel and Kieser. 5 This test is exact and prevents potential problems with pre-specifying the landmark time based on historical control rates. Specifically, those prespecified times may differ from the associated historical times due to secular shifts in the distribution due to changing supportive care or changing pathogens. The R package nivm to calculate the control quantile test and associated confidence intervals is available on http://cran.r-project.org/.
Our method avoids pre-specifying a landmark time where the difference in failure rates is compared; instead, we pre-specify the target control proportion of failures that determine the time when we compare the failure rates. Just as the previous method requires extensive discussions with regulators and care with choosing the landmark time, our method requires similar discussions and care in choosing the pre-specified target proportion of control failures. That decision will depend on the application, and it is difficult to give general guidance across applications; however, we can say that the target proportion should be chosen so that there is a very high probability that the target proportion of failures will be reached within the time frame planned for the study. If the study is stopped before the pre-specified proportion is reached, then only an ad hoc analysis may be done, and the resulting statistical properties will be unclear.
If there is right censoring before the pre-specified proportion of controls have failed, then the test cannot be applied as described. If the censoring is independent of the failure time and the group membership and if there is only a small amount of censoring, then removing the censored individuals should not overly bias the comparison between the groups. A more rigorous method for handling this type of censoring requires further work. 
